Jump Financial LLC Takes Position in Insmed Incorporated (NASDAQ:INSM)

Jump Financial LLC purchased a new stake in Insmed Incorporated (NASDAQ:INSM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 3,336 shares of the biopharmaceutical company’s stock, valued at approximately $230,000.

A number of other institutional investors also recently modified their holdings of the company. National Bank of Canada FI lifted its stake in shares of Insmed by 9.7% in the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 147 shares during the period. Abel Hall LLC lifted its stake in shares of Insmed by 4.7% in the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 151 shares during the period. Steward Partners Investment Advisory LLC lifted its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the period. M&T Bank Corp lifted its stake in shares of Insmed by 5.6% in the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock valued at $217,000 after buying an additional 166 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Insmed by 5.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 183 shares during the period.

Insmed Stock Performance

Shares of Insmed stock opened at $69.69 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market cap of $12.67 billion, a P/E ratio of -12.47 and a beta of 1.07. The firm has a 50 day simple moving average of $74.38 and a 200 day simple moving average of $73.57. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Sell-side analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

INSM has been the subject of several research reports. Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Guggenheim restated a “buy” rating and set a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Stifel Nicolaus cut their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Finally, HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Insmed in a research note on Tuesday, April 22nd. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $94.00.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the transaction, the chief executive officer now directly owns 379,534 shares of the company’s stock, valued at $29,580,879.96. This trade represents a 4.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the transaction, the chief financial officer now directly owns 118,863 shares in the company, valued at approximately $9,545,887.53. This represents a 13.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 471,797 shares of company stock valued at $37,621,239. 3.00% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.